Overzicht lopende oncologische studies​

Amgen-20140299

A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases.

  • Atezolizumab (anti-PD-L1) IV in combinatie met TVEC injecties in levermetastasen

MASTERKEY-318

A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab.

  • TVEC injecties in HCC met of zonder Pembrolizumab (anti-PD-1) IV

M15-891

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, as Monotherapy and in Combination with Another Anti-Cancer Therapy in Subjects with Advanced Solid Tumors. (M15-891).

  • ABBV-181 (nieuw anti-PD1 antilichaam) in monotherapie of in combinatie met ofwel Rova-T ofwel Venetoclax

ACT15377

A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies.

  • Atezolizumab (anti-PD-L1) in combinatie met isatuximab (anti-CD38)

BP40234

An open-label, multicenter, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2v) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic solid tumors.

  • Atezolizumab (anti-PD-L1) in combinatie met RO6874281 (FAP-targeted IL-2v)

CA044-001

Phase I/II Study of BMS-986310 Administered Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors.

  • Nivolumab (anti-PD-1) in combinatie met BMS-986310 (orale prostaglandine-receptor EP4 antagonist)

GO39733

A Phase Ia/Ib Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Tumors.

  • Atezolizumab (anti-PD-L1) in combinatie met een gepersonaliseerd anti-kanker vaccin (IV)

BI1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit. 

  • Monotherapie met BI 894999, een orale BET-inhibitor

J1C-MC-JZDA

A Phase 1a/1b Study of LY3415244, a Bispecific Antibody in Patients with Advanced Solid Tumors.
  • Bispecifiek antilichaam gericht tegen zowel PD-L1 als TIM-3

INCAGN 1876-201

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies.

  • Nivolumab (anti-PD-1) in combinatie met INCAGN01876 (agonist anti-GITR antilichaam)

IO-001

Phase I/Ib First-in-Human study of EOS100850 in patients with advanced solid tumors.

  • Monotherapie met EOS100850, een orale adenosine A2a receptor antagonist

CA027-002

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers.

  • Nivolumab (anti-PD-1) in combinatie met BMS-986253, een anti-IL8 monoclonaal antilichaam

J1E-MC-JZEA

A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors

  • Bispecifiek antilichaam gericht tegen zowel PD-1 als PD-L1.

XL184

A Phase 1b Dose-Escalation Study of Cabozantinib Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors.

  • Atezolizumab (anti-PD-L1) in combinatie met Cabozantinib (tyrosine kinase inhibitor) of - in bepaalde cohorten - Cabozantinib monotherapie.

I9L-MC-JZCA(b)

A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors.

  • LY3300054 (anti-PD-L1) in combinatie met LY3381916 (IDO-1 Inhibitor)